1. Home >
  2. AstraZeneca Acquires Takeda Pharmaceutical Company - Core Respiratory Business

M&A Deal Summary

AstraZeneca Acquires Takeda Pharmaceutical Company - Core Respiratory Business

On December 16, 2015, AstraZeneca acquired life science company Takeda Pharmaceutical Company - Core Respiratory Business from Takeda for 575M USD

Acquisition Highlights
  • This is AstraZeneca’s 9th transaction in the Life Science sector.
  • This is AstraZeneca’s 12th largest (disclosed) transaction.
  • This is AstraZeneca’s 1st transaction in Japan.

M&A Deal Summary
Date 2015-12-16
Target Takeda Pharmaceutical Company - Core Respiratory Business
Sector Life Science
Buyer(s) AstraZeneca
Sellers(s) Takeda
Deal Type Divestiture
Deal Value 575M USD

Target

Takeda Pharmaceutical Company - Core Respiratory Business

Japan
Takeda Pharmaceutical Company Limited's core respiratory business includes the expansion of rights to roflumilast (marketed as Daliresp in the US and Daxas in other countries), the only approved oral PDE4 inhibitor for the treatment of chronic obstructive pulmonary disease (COPD).

Search 204,714 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

AstraZeneca

Cambridge, United Kingdom
Category Company
Founded 1992
Sector Life Science
Employees83,100
Revenue 54.1B USD (2024)
DESCRIPTION
Main office on AstraZeneca's campus in Waltham, Massachusetts.
Main office on AstraZeneca's campus in Waltham, Massachusetts.

AstraZeneca is a global biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines in several major disease areas, including oncology, cardiovascular, renal & metabolism, and respiratory & immunology. AstraZeneca was founded in 1992 and is based in Cambridge, United Kingdom.

DEAL STATS #
Overall 11 of 21
Sector (Life Science) 9 of 19
Type (Divestiture) 3 of 6
Country (Japan) 1 of 1
Year (2015) 2 of 3
Size (of disclosed) 12 of 18
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2015-11-05 ZS Pharma

Coppell, Texas, United States

ZS Pharma, founded in 2008, is a privately held specialty pharmaceutical company based in Coppell, Texas and Menlo Park, CA. Our core focus is the research and development of highly selective ion-trap therapies to treat serious medical conditions.

Buy $2.7B
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2015-12-17 Acerta Pharma BV

Oss, Netherlands

Acerta Pharma is a cancer drug developer with operations in the Netherlands and in California.

Buy $4.0B

Seller(S) 1

SELLER

Takeda

Tokyo, Japan
Category Company
Founded 1781
Sector Life Science
Employees47,347
Revenue 4.03T JPY (2023)
DESCRIPTION
Takeda's corporate headquarters in Tokyo, Japan.
Takeda's corporate headquarters in Tokyo, Japan.

Takeda is a global biopharmaceutical organization committed to improving the health and well-being of people worldwide. Takeda is dedicated to addressing unmet medical needs through the development of innovative and transformative therapies. The Company's diverse portfolio encompasses a wide range of therapeutic areas, including oncology, gastroenterology, rare diseases, neuroscience, and vaccines. Takeda was originally established in 1781 and is based in Tokyo, Japan.

DEAL STATS #
Overall 1 of 6
Sector (Life Science) 1 of 3
Type (Divestiture) 1 of 6
Country (Japan) 1 of 5
Year (2015) 1 of 1
Size (of disclosed) 1 of 4
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2013-05-08 Inviragen

Fort Collins, Colorado, United States

Inviragen is focused on developing vaccines to protect against infectious diseases worldwide.

Buy $35M
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2016-01-05 Baxalta - Biologics Manufacturing Facility

Brooklyn Park, Minnesota, United States

Baxalta - Biologics Manufacturing Facility is a producer of Entyvio® (vedolizumab) and other biologic products.

Buy -
Mergr

Product

Company

Legal